RWA Wealth Partners LLC Has $11.40 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• RWA Wealth Partners LLC reduced its holdings in Regeneron Pharmaceuticals by 2.5%, owning 17,970 shares valued at approximately $11.4 million after selling 456 shares in the first quarter.
• Regeneron Pharmaceuticals reported $12.89 EPS for the quarter, significantly exceeding analyst expectations of $8.43, with a revenue of $3.68 billion, surpassing estimates of $3.30 billion.
• The company announced a quarterly dividend of $0.88 per share, representing an annual yield of 0.6%, and has a payout ratio of 8.87%.

RWA Wealth Partners LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 17,970 shares of the biopharmaceutical company's stock after selling 456 shares during the quarter. RWA Wealth Partners LLC's holdings in Regeneron Pharmaceuticals were worth $11,397,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Qtron Investments LLC increased its position in shares of Regeneron Pharmaceuticals by 37.5% in the first quarter. Qtron Investments LLC now owns 1,945 shares of the biopharmaceutical company's stock valued at $1,234,000 after acquiring an additional 530 shares during the last quarter. Brooklyn Investment Group increased its position in shares of Regeneron Pharmaceuticals by 29.4% in the first quarter. Brooklyn Investment Group now owns 510 shares of the biopharmaceutical company's stock valued at $323,000 after acquiring an additional 116 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $288,000. Corient IA LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $317,000. Finally, Cambiar Investors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $31,908,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded up $19.23 during trading on Wednesday, reaching $591.01. 1,298,509 shares of the stock were exchanged, compared to its average volume of 973,488. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The firm has a market cap of $62.64 billion, a PE ratio of 14.89, a PEG ratio of 1.90 and a beta of 0.33. The stock has a 50-day moving average price of $547.75 and a 200-day moving average price of $593.42. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter in the previous year, the company posted $11.56 earnings per share. The business's revenue was up 3.6% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Analyst Ratings Changes

A number of equities analysts have weighed in on REGN shares. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a research report on Friday, August 1st. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a "buy" rating and a $890.00 price target on the stock. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Morgan Stanley reissued an "overweight" rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, The Goldman Sachs Group lowered their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $829.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.